Apollon Wealth Management’s Gain Therapeutics GANX Stock Holding History

Apollon Wealth Management’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$51.4K	Buy	26,500 +6,675	+34%	+$14.5K	﹤0.01%	1368
2025 Q4	$63.8K	Buy	+19,825	New	+$52.9K	﹤0.01%	1274

Other funds holding GANX

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

PCM

Potomac Capital Management New York $115M AUM

Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

DCM

DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Apollon Wealth Management's GANX Position: Q1 2026 in Review

Apollon Wealth Management increased its Gain Therapeutics (GANX) stake by 34% in Q1 2026, buying an estimated $14.5K and bringing the position to 26,500 shares worth $51.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1368.

Apollon Wealth Management first reported a position in GANX in Q4 2025 and has held it in 2 quarters since. The position peaked at $63.8K in Q4 2025. 42 funds tracked by Wall St. Rank hold GANX as of Q1 2026.

Apollon Wealth Management held 26,500 shares of Gain Therapeutics worth $51.4K as of Q1 2026.
Apollon Wealth Management bought 6,675 Gain Therapeutics shares in Q1 2026, an estimated $14.5K.
Gain Therapeutics made up ﹤0.01% of Apollon Wealth Management's portfolio in Q1 2026, its #1368 holding.
Apollon Wealth Management first reported a position in Gain Therapeutics in Q4 2025 and has held it in 2 quarters since.
Apollon Wealth Management's Gain Therapeutics position peaked at $63.8K in Q4 2025.
42 funds tracked by Wall St. Rank held Gain Therapeutics as of Q1 2026.

Based on Apollon Wealth Management's 13F filing for Q1 2026, filed 22 Apr 2026.